Citazione non strutturata

[1] Bachmann CJ, Aagaard L, Burcu M, Glaeske G, Kalverdijk LJ, Petersen I, et al. Trends and patterns of antidepressant use in children and adolescents from five western countries, 2005-2012. European Neuropsychopharmacology 2016; 26: 411-419.

https://doi.org/10.1016/j.euroneuro.2016.02.001

Citazione non strutturata

[2] Hartz I, Skurtveit S, Steffenak AK, Karlstad O, Handal M. Psychotropic drug use among 0-17 year olds during 2004-2014: a nationwide prescription database study. BMC Psychiatry 2016; 16: 12.

https://doi.org/10.1186/s12888-016-0716-x

Citazione non strutturata

[3] Steinhausen HC, Bisgaard C. Nationwide time trends in dispensed prescriptions of psychotropic medication for children and adolescents in denmark. Acta Psychiatrica Scandinavica 2014; 129: 221-231.

https://doi.org/10.1111/acps.12155

Citazione non strutturata

[4] Weinstein SJ, House SA, Chang CH, Wasserman JR, Goodman DC, Morden NE. Small geographic area variations in prescription drug use. Pediatrics 2014; 134: 563-570.

https://doi.org/10.1542/peds.2013-4250

Citazione non strutturata

[5] Zoega H, Baldursson G, Hrafnkelsson B, Almarsdottir AB, Valdimarsdottir U, Halldorsson M. Psychotropic drug use among Icelandic children: a nationwide population-based study. Journal of Child and Adolescent Psychopharmacology 2009; 19: 757-764.

https://doi.org/10.1089/cap.2009.0003

Citazione non strutturata

[6] Piovani D, Clavenna A, Cartabia M, Bonati M. Psychotropic medicine prescriptions in Italian youths: a multiregional study. European Child and Adolescent Psychiatry 2016; 25: 235-245.

https://doi.org/10.1007/s00787-015-0726-0

Citazione non strutturata

[7] Le Noury J, Nardo JM, Healy D, Jureidini J, Raven M, Tufanaru C, Abi-Jaoude E. Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence. BMJ 2015; 351:h4320.

Citazione non strutturata

[8] Clavenna A, Andretta M, Pilati P, Dusi M, Gangemi M, Gattoni MB, et al. Antidepressant and antipsychotic use in an Italian pediatric population. BMC Pediatrics 2011; 11: 40.

https://doi.org/10.1186/1471-2431-11-40

Citazione non strutturata

[9] Ivarsson T, Skarphedinsson G, Kornor H, Axelsdottir B, Biedilae S, Heyman I et al. The place of and evidence for serotonin reuptake inhibitors (SRIs) for obsessive compulsive disorder (OCD) in children and adolescents: Views based on a systematic review and meta-analysis. Psychiatry Research 2015; 227: 93-103.

https://doi.org/10.1016/j.psychres.2015.01.015

Citazione non strutturata

[10] Hazell P, Mirzaie M. Tricyclic drugs for depression in children and adolescents. Cochrane Database Systematic Review 2013; 6: CD002317.

https://doi.org/10.1002/14651858.CD002317.pub2

Citazione non strutturata

[11] Hetrick SE, McKenzie JE, Cox GR, Simmons MB, Merry SN. Newer generation antidepressants for depressive disorders in children and adolescents. Cochrane Database Systematic Review 2012; 11: CD004851.

https://doi.org/10.1002/14651858.CD004851.pub3

10.1016/S0140-6736(16)30385-313]StrawnJR,WelgeJA,WehryAM,KeeshinB,RynnMA.Efficacyandtolerabilityofantidepressantsinpediatricanxietydisorders:asystematicreviewandmeta-analysis.DepressionandAnxiety2015;32:149-157

Citazione non strutturata

[14] Zuddas A, Zanni R, Usala T. Second generation antipsychotics (SGAs) for nonpsychotic disorders in children and adolescents: a review of the randomized controlled studies. European Neuropsychopharmacology 2011; 21: 600-620.

https://doi.org/10.1016/j.euroneuro.2011.04.001

Citazione non strutturata

[15] Stafford MR, Mayo-Wilson E, Loucas CE, James A, Hollis C, Birchwood M, et al. Efficacy and safety of pharmacological and psychological interventions for the treatment of psychosis and schizophrenia in children, adolescents and young adults: a systematic review and meta-analysis. PLoS One 2015; 10: e0117166.

https://doi.org/10.1371/journal.pone.0117166

Citazione non strutturata

[16] Caccia S, Clavenna A, Bonati M. Antipsychotic drug toxicology in children. Expert Opinion on Drug Metabolism & Toxicology 2011; 7: 591-608.

https://doi.org/10.1517/17425255.2011.562198

Citazione non strutturata

[17] Chan E, Fogler JM, Hammerness PG. Treatment of attention-deficit/hyperactivity disorder in adolescents: a systematic review. The Journal of the American Medical Association 2016; 315: 1997-2008.

https://doi.org/10.1001/jama.2016.5453

Citazione non strutturata

[18] Simeon JG, Ferguson HB, Knott V, Roberts N, Gauthier B, Dubois C, et al. Clinical, cognitive, and neurophysiological effects of alprazolam in children and adolescents with overanxious and avoidant disorders. Journal of the American Academy of Child and Adolescent Psychiatry 1992; 31: 29-33.

https://doi.org/10.1097/00004583-199201000-00006

Citazione non strutturata

[19] Armour A, Gottschlich MM, Khoury J, Warden GD, Kagan RJ. A randomized, controlled prospective trial of zolpidem and haloperidol for use as sleeping agents in pediatric burn patients. Journal of Burn Care & Research 2008; 29: 238-247.

https://doi.org/10.1097/BCR.0b013e31815f384e

Citazione non strutturata

[20] Blumer JL, Findling RL, Shih WJ, Soubrane C, Reed MD. Controlled clinical trial of zolpidem for the treatment of insomnia associated with attentiondeficit/hyperactivity disorder in children 6 to 17 years of age. Pediatrics 2009; 123: e770-e776.

https://doi.org/10.1542/peds.2008-2945

Citazione non strutturata

[21] Bonati M. Psicofarmaci nell’età evolutiva. Roma: Il Pensiero Scientifico Editore; 2015.

Citazione non strutturata

[22] Zemrak WR, Kenna GA. Association of antipsychotic and antidepressant drugs with Q-T interval prolongation. American Journal of Health-System Pharmacy 2008; 65: 1029-1038.

https://doi.org/10.2146/ajhp070279

Citazione non strutturata

[23] Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Archives of General Psychiatry 2006; 63: 332-339.

https://doi.org/10.1001/archpsyc.63.3.332

Citazione non strutturata

[24] Stone M, Laughren T, Jones ML, Levenson M, Holland PC, Hughes A, et al. Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. British Medical Journal 2009; 339: b2880.

https://doi.org/10.1136/bmj.b2880

Citazione non strutturata

[25] Jerrell JM. Neuroendocrine-related adverse events associated with antidepressant treatment in children and adolescents. CNS Neuroscienze & Therapeutics 2010; 16: 83-90.

https://doi.org/10.1111/j.1755-5949.2009.00106.x

Citazione non strutturata

[26] Fraguas D, Correll CU, Merchan-Naranjo J, Rapado-Castro M, Parellada M, Moreno C, et al. Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons. European Neuropsychopharmacology 2011; 21: 621-645.

https://doi.org/10.1016/j.euroneuro.2010.07.002

Citazione non strutturata

[27] De Hert M, Dobbelaere M, Sheridan EM, Cohen D, Correll CU. Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice. European Psychiatry 2011; 26: 144-158.

https://doi.org/10.1016/j.eurpsy.2010.09.011

Citazione non strutturata

[28] Galling B, Roldan A, Nielsen RE, Nielsen J, Gerhard T, Carbon M, et al. Type 2 diabetes mellitus in youth exposed to antipsychotics: a systematic review and meta-analysis. JAMA Psychiatry 2016; 73: 247-259.

https://doi.org/10.1001/jamapsychiatry.2015.2923

Citazione non strutturata

[29] Clavenna A, Bonati M. Safety and tolerability of medications for adhd. In: Spina E, Trifirò G, ed. Pharmacovigilance in Psychiatry. ADIS; 2016. 233-253.

https://doi.org/10.1007/978-3-319-24741-0_12

Citazione non strutturata

[30] Stein MA, Weiss M, Hlavaty L. ADHD treatments, sleep, and sleep problems: complex associations. Neurotherapeutics 2012; 9: 509-517.

https://doi.org/10.1007/s13311-012-0130-0

Citazione non strutturata

[31] Graham J, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Dittmann RW, et al. European guidelines on managing adverse effects of medication for adhd. European Child and Adolescent Psychiatry 2011; 20: 17-37.

https://doi.org/10.1007/s00787-010-0140-6

Citazione non strutturata

[32] Gould MS, Walsh BT, Munfakh JL, Kleinman M, Duan N, Olfson M, et al. Sudden death and use of stimulant medications in youths. American Journal of Psychiatry 2009; 166: 992-1001.

https://doi.org/10.1176/appi.ajp.2009.09040472

Citazione non strutturata

[33] Hammerness PG, Karampahtsis C, Babalola R, Alexander ME. Attentiondeficit/hyperactivity disorder treatment: what are the long-term cardiovascular risks? Expert Opinion on Drug Safety 2015; 1-9.

Citazione non strutturata

[34] Shin J-Y, Roughead EE, Park B-J, Pratt NL. Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self controlled case study. BMJ 2016; 353:i2550.

https://doi.org/10.1136/bmj.i2550

Citazione non strutturata

[35] Bangs ME, Tauscher-Wisniewski S, Polzer J, Zhang S, Acharya N, Desaiah D, et al. Meta-analysis of suicide-related behavior events in patients treated with atomoxetine. Journal of the American Academy of Child and Adolescent Psychiatry 2008; 47: 209-218.

https://doi.org/10.1097/chi.0b013e31815d88b2

Citazione non strutturata

[36] Bangs ME, Wietecha LA, Wang S, Buchanan AS, Kelsey DK. Meta-analysis of suicide-related behavior or ideation in child, adolescent, and adult patients treated with atomoxetine. Journal of Child and Adolescent Psychopharmacology 2014; 24: 426-434.

https://doi.org/10.1089/cap.2014.0005

Citazione non strutturata

[37] Mosholder AD, Gelperin K, Hammad TA, Phelan K, Johann-Liang R. Hallucinations and other psychotic symptoms associated with the use of attention-deficit/hyperactivity disorder drugs in children. Pediatrics 2009; 123: 611-616.

https://doi.org/10.1542/peds.2008-0185

Citazione non strutturata

[38] Humphreys KL, Eng T, Lee SS. Stimulant medication and substance use outcomes: a meta-analysis. JAMA Psychiatry 2013; 70: 740-749.

https://doi.org/10.1001/jamapsychiatry.2013.1273

Citazione non strutturata

[39] Wilens TE, Gignac M, Swezey A, Monuteaux MC, Biederman J. Characteristics of adolescents and young adults with adhd who divert or misuse their prescribed medications. Journal of the American Academy of Child and Adolescent Psychiatry 2006; 45: 408-414.

https://doi.org/10.1097/01.chi.0000199027.68828.b3

Citazione non strutturata

[40] Lader M. Benzodiazepine harm: how can it be reduced? Br J Clin Pharmacol. 2014 Feb;77(2):295-301

https://doi.org/10.1111/j.1365-2125.2012.04418.x

Citazione non strutturata

[41] Brett J, Murnion B. Management of benzodiazepine misuse and dependence. Aust Prescr. 2015;38(5):152-5

https://doi.org/10.18773/austprescr.2015.055